Skip to main content
    • Aa
    • Aa

Regulation of Foods and Drugs and Libertarian Ideals: Perspectives of a Fellow-Traveler*

  • Daniel D. Polsby (a1)
  • DOI:
  • Published online: 01 January 2009

For one with libertarian sympathies, the official regulation of foods and drugs is presumptively a bad thing. One is most accustomed to seeing the argument in debates about legalizing marijuana and other hedonic drugs. And it remains a very good if by now well-trafficked question, which will be more well-trafficked still by the time this essay ends, why government should be in the business of telling people what sorts of chemical moodenhancers they may take. But as the criminologist James Jacobs has pointed out, to ask this question is to put in play matters far larger and more important than marijuana. What business is it of government to say what medicines may be sold and by whom they may be sold? Why should certain chemical agents be available to willing buyers only with a doctor's scrip, and other agents, such as unproved drugs or devices, forbidden to all, even with medical permission? If libertarians answer these questions impatiently, then admirers of the administrative welfare state (“statists”) will be happy to play rope-a-dope with them, chattering on about the endearing eccentricities of libertarians' assumptions and avoiding the challenge to articulate and defend their own increasingly shabby-looking principles. Those principles are much in need of defense. Food and drug laws are among the most well-established offices of regulatory government. They are complicated, hypertechnical, mysterious, and expensive to administer and maintain. One is entitled to suspect that a number of them are carried on more out of habit and routine than out of any authentic conviction that they are the best way, or among the better ways, to provide for the welfare of citizens.

Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

Alfred Blumstein , “Youth Violence, Guns, and the Illicit Drug Industry,” Journal of Criminal Law and Criminology, vol. 86 (1995).

P. Perry , K. Anderson , and W. Yates , “Illicit Anabolic Steroid Use in Athletes: A Case Series Analysis,” American Journal of Sports Medicine, vol. 18 (1990)

W. E. Buckley , “Estimated Prevalence of Anabolic Steroid Use among Male High School Seniors,” Journal of the American Medical Association, vol. 260 (1988), pp. 3441–45.

C. M. Stinton , “Preliminary Indications that Functional Effects of Fetal Caffeine Exposure Can Be Expressed in a Second Generation,” Neurotoxicology and Teratology, vol. 11 (07081989), pp. 357–62.

Henry Blumberg , David Rimland , Donna Carroll , Pamela Terry , and Kaye Wachsmuth , “Rapid Development of Ciprofloxacin Resistance in Methicillin-Susceptable and -Resistant Staphylococcus aureus,” Journal of Infectious Diseases, vol. 163 (1991)

Mitchell Cohen , “Epidemiology of Drug Resistance: Implications for a Post-Microbial Era,” Science, vol. 257 (1992)

Harold Neu , “The Crisis in Antibiotic Resistance,” Science, vol. 257 (1992).

Robert Muder , Carole Brennen , Angella Goetz , Marilyn Wagener , and John Rihs , “Association with Prior Fluoroquinolone Therapy of Widespread Ciprofloxacin Resistance among Gram-Negative Isolates in a Veterans Affairs Medical Center,” Antimicrobial Agents and Chemotherapy, vol. 35 (1991)

Robert Gaynes , Robert Weinstein , William Chamberlin , and Sherwin Kabins , “Antibiotic-Resistant Flora in Nursing Home Patients Admitted to the Hospital,” Archives of Internal Medicine, vol. 145 (1985)

Barbara Murray , “New Aspects of Antimicrobial Resistance and the Resulting Therapeutic Dilemmas,” Journal of Infectious Diseases, vol. 163 (1991)

Thomas O'Brien , “Resistance of Bacteria to Antibacterial Agents: Report of Task Force 2,” Reviews of Infectious Diseases, vol. 9 (1987).

Scott Holmberg , Steven Solomon , and Paul Blake , “Health and Economic Impacts of Anti-Microbial Resistance,” Reviews of Infectious Diseases, vol. 9 (121987), pp. 1065–77.

J. A. DiMasi , “Cost of Innovation in the Pharmaceutical Industry,” Journal of Health and Economics, vol. 10 (1991), p. 126.

J. P. Griffin , “Objectives and Achievements of Regulations in the U.K.,” in International Medicines Regulations: A Forward Look to 1992, ed. Stuart R. Walker and John P. Griffin (Dordrecht: Kluwer, 1989), pp. 73, 87, 117, 130.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Social Philosophy and Policy
  • ISSN: 0265-0525
  • EISSN: 1471-6437
  • URL: /core/journals/social-philosophy-and-policy
Please enter your name
Please enter a valid email address
Who would you like to send this to? *